Literature DB >> 21242367

Addressing missing data in clinical trials.

Thomas R Fleming1.   

Abstract

The reliability and interpretability of results from clinical trials can be substantially reduced by missing data. Frequently used approaches to address these concerns, such as upward adjustments in sample sizes or simplistic methods for handling missing data, including last-observation-carried-forward, complete-case, or worst-case analyses, are usually inadequate. Although rational imputation methods may be useful to treat missingness after it has occurred, these methods depend on untestable assumptions. Thus, the preferred and often only satisfactory approach to addressing missing data is to prevent it. Procedures should be in place to maximize the likelihood that outcome data will be obtained at scheduled times of evaluation for all surviving patients who have not withdrawn consent. To meaningfully reduce missing data, it is important to recognize and address many factors that commonly lead to higher levels of missingness.

Entities:  

Mesh:

Year:  2011        PMID: 21242367      PMCID: PMC3319761          DOI: 10.7326/0003-4819-154-2-201101180-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  16 in total

1.  (Almost) everything you ever wanted to know about informed consent. [Review of: Faden, RR and Beauchamp, TL. A history and theory of informed concsent. New York and Oxford: Oxford University Press, 1986].

Authors:  A M Capron
Journal:  Med Humanit Rev       Date:  1987-01

2.  A method to reduce loss to follow-up in clinical trials: informed, withdrawal of consent.

Authors:  John G F Cleland; Christian Torp-Pedersen; Alison P Coletta; Michael J Lammiman
Journal:  Eur J Heart Fail       Date:  2004-01       Impact factor: 15.534

Review 3.  Clinical trials in psychiatry: should protocol deviation censor patient data?

Authors:  P W Lavori
Journal:  Neuropsychopharmacology       Date:  1992-01       Impact factor: 7.853

4.  Statistical considerations in the intent-to-treat principle.

Authors:  J M Lachin
Journal:  Control Clin Trials       Date:  2000-06

5.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

6.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.

Authors:  L A Guay; P Musoke; T Fleming; D Bagenda; M Allen; C Nakabiito; J Sherman; P Bakaki; C Ducar; M Deseyve; L Emel; M Mirochnick; M G Fowler; L Mofenson; P Miotti; K Dransfield; D Bray; F Mmiro; J B Jackson
Journal:  Lancet       Date:  1999-09-04       Impact factor: 79.321

7.  Combined endpoints: can we use them?

Authors:  Jacobus Lubsen; Bridget-Anne Kirwan
Journal:  Stat Med       Date:  2002-10-15       Impact factor: 2.373

8.  Randomized trial of trauma-focused group therapy for posttraumatic stress disorder: results from a department of veterans affairs cooperative study.

Authors:  Paula P Schnurr; Matthew J Friedman; David W Foy; M Tracie Shea; Frank Y Hsieh; Philip W Lavori; Shirley M Glynn; Melissa Wattenberg; Nancy C Bernardy
Journal:  Arch Gen Psychiatry       Date:  2003-05

9.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.

Authors:  J Brooks Jackson; Philippa Musoke; Thomas Fleming; Laura A Guay; Danstan Bagenda; Melissa Allen; Clemensia Nakabiito; Joseph Sherman; Paul Bakaki; Maxensia Owor; Constance Ducar; Martina Deseyve; Anthony Mwatha; Lynda Emel; Corey Duefield; Mark Mirochnick; Mary Glenn Fowler; Lynne Mofenson; Paolo Miotti; Maria Gigliotti; Dorothy Bray; Francis Mmiro
Journal:  Lancet       Date:  2003-09-13       Impact factor: 79.321

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  32 in total

1.  Some essential considerations in the design and conduct of non-inferiority trials.

Authors:  Thomas R Fleming; Katherine Odem-Davis; Mark D Rothmann; Yuan Li Shen
Journal:  Clin Trials       Date:  2011-08       Impact factor: 2.486

2.  A randomized trial of continuous versus interrupted chest compressions in out-of-hospital cardiac arrest: rationale for and design of the Resuscitation Outcomes Consortium Continuous Chest Compressions Trial.

Authors:  Siobhan P Brown; Henry Wang; Tom P Aufderheide; Christian Vaillancourt; Robert H Schmicker; Sheldon Cheskes; Ron Straight; Peter Kudenchuk; Laurie Morrison; M Riccardo Colella; Joseph Condle; George Gamez; David Hostler; Tami Kayea; Sally Ragsdale; Shannon Stephens; Graham Nichol
Journal:  Am Heart J       Date:  2014-11-20       Impact factor: 4.749

3.  Impact of missing data on analysis of postoperative cognitive decline (POCD).

Authors:  Susan K DeCrane; Laura P Sands; Kristen Marie Young; Glen DePalma; Jacqueline M Leung
Journal:  Appl Nurs Res       Date:  2013-01-03       Impact factor: 2.257

4.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Peter C Gøtzsche; Douglas G Altman; Howard Mann; Jesse A Berlin; Kay Dickersin; Asbjørn Hróbjartsson; Kenneth F Schulz; Wendy R Parulekar; Karmela Krleza-Jeric; Andreas Laupacis; David Moher
Journal:  BMJ       Date:  2013-01-08

5.  Addressing missing data in clinical studies of kidney diseases.

Authors:  Maria E Montez-Rath; Wolfgang C Winkelmayer; Manisha Desai
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-07       Impact factor: 8.237

6.  A guide to missing data for the pediatric nephrologist.

Authors:  Nicholas G Larkins; Jonathan C Craig; Armando Teixeira-Pinto
Journal:  Pediatr Nephrol       Date:  2018-03-13       Impact factor: 3.714

7.  Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.

Authors:  Ganesh Raghu; Harold R Collard; Kevin J Anstrom; Kevin R Flaherty; Thomas R Fleming; Talmadge E King; Fernando J Martinez; Kevin K Brown
Journal:  Am J Respir Crit Care Med       Date:  2012-04-13       Impact factor: 21.405

8.  Primary outcomes for resuscitation science studies: a consensus statement from the American Heart Association.

Authors:  Lance B Becker; Tom P Aufderheide; Romergryko G Geocadin; Clifton W Callaway; Ronald M Lazar; Michael W Donnino; Vinay M Nadkarni; Benjamin S Abella; Christophe Adrie; Robert A Berg; Raina M Merchant; Robert E O'Connor; David O Meltzer; Margo B Holm; William T Longstreth; Henry R Halperin
Journal:  Circulation       Date:  2011-10-03       Impact factor: 29.690

9.  Minimally invasive facet restoration implant for chronic lumbar zygapophysial pain: 1-year outcomes.

Authors:  Hans-Jörg Meisel; Konrad Seller; Achim L Th; Karin B Ttner-Janz; Peter Stosberg; Alexander Moser; Larry E Miller; Jon E Block; Luiz Pimenta
Journal:  Ann Surg Innov Res       Date:  2014-10-18

10.  Addressing the challenges of obtaining functional outcomes in traumatic brain injury research: missing data patterns, timing of follow-up, and three prognostic models.

Authors:  Leila R Zelnick; Laurie J Morrison; Sean M Devlin; Eileen M Bulger; Karen J Brasel; Kellie Sheehan; Joseph P Minei; Jeffrey D Kerby; Samuel A Tisherman; Sandro Rizoli; Riyad Karmy-Jones; Rardi van Heest; Craig D Newgard
Journal:  J Neurotrauma       Date:  2014-05-08       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.